A randomized phase III clinical trial of sequential capecitabine or 5-FU plus bevacizumab (Cape/5-FU+Bmab) followed by Cape/5-FU plus oxaliplatin plus Bmab (CapeOX/mFOLFOX6+Bmab) versus combination CapeOX/mFOLFOX6+Bmab in advanced colorectal cancer: The C-MedSci.cn

A randomized phase III clinical trial of sequential capecitabine or 5-FU plus bevacizumab (Cape/5-FU+Bmab) followed by Cape/5-FU plus oxaliplatin plus Bmab (CapeOX/mFOLFOX6+Bmab) versus combination CapeOX/mFOLFOX6+Bmab in advanced colorectal cancer: The C

Ojima, H; Mishima, H; Sawaki, A; Nagasaka, T; Shimokawa, M; Inukai, M; Shinozaki, K; Tanioka, H; Nasu, J; Nishina, T; Hazama, S; Okajima, M; Tsuji, A; Tsuji, Y; Munemoto, Y; Yamaguchi, S; Yamaguchi, Y

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (4):

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

A randomized phase III clinical trial of sequential capecitabine or 5-FU plus bevacizumab (Cape/5-FU+Bmab) followed by Cape/5-FU plus oxaliplatin plus Bmab (CapeOX/mFOLFOX6+Bmab) versus combination CapeOX/mFOLFOX6+Bmab in advanced colorectal cancer: The C

科室

工具

服务